

Francesco A Piazza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3751259/publications.pdf>

Version: 2024-02-01

138
papers

3,177
citations

196777
29
h-index

206121
51
g-index

142
all docs

142
docs citations

142
times ranked

4786
citing authors

#	ARTICLE	IF	CITATIONS
1	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876.	1.7	31
2	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
3	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Cancers</i> , 2022, 14, 338.	1.7	2
4	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP53</i> disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
5	Anaemia during venetoclax ramp-up phase: Do not forget unusual causes. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	1
6	Metabolic control of epigenetic rearrangements in B cell pathophysiology. <i>Open Biology</i> , 2022, 12, 220038.	1.5	1
7	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BAiT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
8	Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry. <i>Acta Haematologica</i> , 2021, 144, 259-263.	0.7	4
9	Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. <i>European Journal of Haematology</i> , 2021, 106, 737-739.	1.1	10
10	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. <i>PLoS ONE</i> , 2021, 16, e0247717.	1.1	10
11	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
12	Targeting Protein Kinases in Blood Cancer: Focusing on CK1 α and CK2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3716.	1.8	18
13	Lymph node core needle biopsy in lymphoproliferative disorders—Authors' reply to Al-Abbadi and colleagues. <i>European Journal of Haematology</i> , 2021, 107, 297-298.	1.1	2
14	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 682658.	1.3	2
15	Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6548.	1.3	2
16	Protein Kinase CK1 α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 733848.	1.3	4
17	The Risk of Malignancies in Celiac Disease—A Literature Review. <i>Cancers</i> , 2021, 13, 5288.	1.7	15
18	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 5453.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2427-2427.	0.6	3
20	Circular RNA Dysregulation Characterizes Symptomatic T-LGL Leukemia Patients with <i>STAT3</i> Mutation. <i>Blood</i> , 2021, 138, 1134-1134.	0.6	0
21	Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. <i>Cancers</i> , 2021, 13, 6089.	1.7	10
22	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020, 34, 1462-1466.	3.3	30
23	New responsibilities for aged kinases in B-lymphomas. <i>Hematological Oncology</i> , 2020, 38, 3-11.	0.8	8
24	Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia: Targets and Therapy, 2020, Volume 13, 9679-9688.	1.0	19
25	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. <i>Hematological Oncology</i> , 2020, 38, 823-826.	0.8	16
26	A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. <i>Annals of Hematology</i> , 2020, 99, 2715-2717.	0.8	2
27	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478.	2.0	7
28	Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research. <i>Frontiers in Oncology</i> , 2020, 10, 802.	1.3	3
29	Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. <i>European Journal of Haematology</i> , 2020, 105, 468-475.	1.1	21
30	Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. <i>Blood Cancer Journal</i> , 2020, 10, 18.	2.8	14
31	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. <i>Cells</i> , 2020, 9, 768.	1.8	27
32	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	1.2	4
33	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020, 136, 33-34.	0.6	1
34	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. <i>British Journal of Haematology</i> , 2019, 185, 193-197.	1.2	24
35	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. <i>Cell Death Discovery</i> , 2019, 5, 98.	2.0	22
36	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	0.8	13

#	ARTICLE	IF	CITATIONS
37	ROBUST: First report of phase III randomized study of lenalidomide/R ² -CHOP (R ² -CHOP) vs placebo/R ² -CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematological Oncology, 2019, 37, 36-37.	0.8	82
38	HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 145, 3089-3100.	2.3	32
39	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 678-685.e4.	0.2	25
40	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. Oncologist, 2019, 24, e720-e729.	1.9	52
41	Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study. British Journal of Haematology, 2019, 186, e13-e17.	1.2	3
42	MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). HemaSphere, 2019, 3, e305.	1.2	4
43	PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE. Hematological Oncology, 2019, 37, 455-456.	0.8	0
44	Immune Profiling of Plasma Cell Dyscrasias Reveals a Therapy Related T-Cell Modulation in Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e87.	0.2	0
45	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. Cancers, 2019, 11, 1939.	1.7	39
46	Peripheral nervous system involvement in lymphomas. Journal of the Peripheral Nervous System, 2019, 24, 5-18.	1.4	44
47	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. British Journal of Haematology, 2019, 185, 940-944.	1.2	49
48	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Human Pathology, 2019, 85, 251-259.	1.1	6
49	PS1431 IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS. HemaSphere, 2019, 3, 659.	1.2	1
50	Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. Blood, 2019, 134, 1539-1539.	0.6	0
51	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HROoL) Analysis of the International Robust Study. Blood, 2019, 134, 3475-3475.	0.6	0
52	Overexpression and Targeted Activation of the Protein Phosphatases SHP-1 Abrogates Survival Pathways in Large Granular Lymphocyte Leukemia (LGLL). Blood, 2019, 134, 2798-2798.	0.6	0
53	Whole Exome Sequencing Analysis in Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) Patients Fails to Detect Significant Viral Load. Blood, 2019, 134, 5214-5214.	0.6	0
54	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 366-369.	0.8	6
56	Rituximab, bendamustine and cytarabine (Râ€BAC) in patients with relapsedâ€refractory aggressive Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2018, 93, E386-E389.	2.0	4
57	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. <i>Blood Cancer Journal</i> , 2018, 8, 51.	2.8	20
58	Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission. <i>Journal of the Neurological Sciences</i> , 2018, 392, 63-64.	0.3	4
59	Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1512.	1.8	16
60	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. <i>Annals of Hematology</i> , 2018, 97, 2001-2003.	0.8	0
61	Dabigatran in ibrutinibâ€treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018, 36, 801-803.	0.8	4
62	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	0.6	6
63	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	0.6	2
64	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4511-4511.	0.6	8
65	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. <i>Current Cancer Drug Targets</i> , 2018, 18, 608-616.	0.8	10
66	Calcium Mobilization in Unfavorable-Prognosis Chronic Lymphocytic Leukemia Patients Mediates Focal Adhesion Kinase (FAK) Cleavage, Thereby Its Activation. <i>Blood</i> , 2018, 132, 5537-5537.	0.6	0
67	Insights into the Molecular Mechanism Accounting for Neutropenia in T-Large Granular Lymphocytes Leukemia. <i>Blood</i> , 2018, 132, 1575-1575.	0.6	0
68	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2017, 178, 81-93.	1.2	25
69	Aberrant expression of <sc>CD</sc>10 and <sc>BCL</sc>6 in mantle cell lymphoma. <i>Histopathology</i> , 2017, 71, 769-777.	1.6	29
70	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. <i>European Journal of Cancer</i> , 2017, 72, 103-111.	1.3	29
71	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. <i>Haematologica</i> , 2017, 102, e140-e143.	1.7	17
72	INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. <i>Hematological Oncology</i> , 2017, 35, 145-146.	0.8	0

#	ARTICLE	IF	CITATIONS
73	DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 194-196.	0.8	0
74	Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B- and T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 345-346.	0.8	0
75	Protein kinase CK2 regulates AKT, NF- κ B and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 292-300.	3.3	55
76	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017, 35, 925-928.	0.8	19
77	Role of protein kinases CK1 \pm and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. <i>Journal of Hematology and Oncology</i> , 2017, 10, 157.	6.9	32
78	Inactivation of CK1 \pm in multiple myeloma empowers drug cytotoxicity by affecting AKT and β -catenin survival signaling pathways. <i>Oncotarget</i> , 2017, 8, 14604-14619.	0.8	30
79	Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. <i>Oncotarget</i> , 2017, 8, 53053-53067.	0.8	27
80	<i>STAT3</i> mutation impacts biological and clinical features of T-LGL leukemia. <i>Oncotarget</i> , 2017, 8, 61876-61889.	0.8	67
81	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. <i>Oncotarget</i> , 2017, 8, 110727-110731.	0.8	23
82	Hematopoietic-Specific CSNK2B Loss in Mice Causes Impaired Erythropoiesis. <i>Blood</i> , 2017, 130, 82-82.	0.6	1
83	Targeting CK2-driven non-oncogene addiction in B-cell tumors. <i>Oncogene</i> , 2016, 35, 6045-6052.	2.6	24
84	Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses.. <i>Blood</i> , 2016, 128, 2093-2093.	0.6	4
85	Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University. <i>Blood</i> , 2016, 128, 2527-2527.	0.6	6
86	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 5563-5563.	0.6	1
87	Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively. <i>Blood</i> , 2016, 128, 4464-4464.	0.6	0
88	The Atypical Gtpase Rho Lies Downstream IL6/STAT3 and Regulates Myeloma Plasma Cells Adhesion/Motility. <i>Blood</i> , 2016, 128, 5661-5661.	0.6	0
89	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. <i>Blood</i> , 2016, 128, 4368-4368.	0.6	0
90	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. <i>Haematologica</i> , 2015, 100, e515-e518.	1.7	48

#	ARTICLE	IF	CITATIONS
91	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. <i>Oncotarget</i> , 2015, 6, 42130-42149.	0.8	39
92	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 612-620.e5.	0.2	26
93	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 592-598.	0.2	2
94	Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience. <i>Blood</i> , 2015, 126, 2710-2710.	0.6	3
95	Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells. <i>Blood</i> , 2015, 126, 3876-3876.	0.6	1
96	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. <i>Oncotarget</i> , 2015, 6, 6544-6552.	0.8	31
97	Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. <i>Leukemia</i> , 2014, 28, 2094-2097.	3.3	14
98	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. <i>Haematologica</i> , 2014, 99, 1826-1833.	1.7	21
99	Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors. <i>Blood</i> , 2014, 124, 5508-5508.	0.6	4
100	Infections in Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia Treated with Azacitidine: Report from a Single Center. <i>Blood</i> , 2014, 124, 5622-5622.	0.6	13
101	Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3321-3321.	0.6	0
102	Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. <i>Leukemia Research</i> , 2013, 37, 221-227.	0.4	28
103	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. <i>Journal of Hematology and Oncology</i> , 2013, 6, 78.	6.9	46
104	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. <i>Blood</i> , 2013, 121, 3843-3854.	0.6	85
105	Protein Kinase CK2 Inhibition Down Modulates the NF- κ B and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. <i>PLoS ONE</i> , 2013, 8, e75280.	1.1	75
106	R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience. <i>Blood</i> , 2013, 122, 3042-3042.	0.6	0
107	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. <i>Clinical Cancer Research</i> , 2012, 18, 1888-1900.	3.2	71
108	Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. <i>Leukemia</i> , 2012, 26, 1174-1179.	3.3	94

#	ARTICLE	IF	CITATIONS
109	Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108.		0
110	CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment. Blood, 2012, 120, 444-444.	0.6	0
111	Analysis of Wnt and Hedgehog Pathways Regulating Protein Kinases CK1 and CK2 in Acute Myeloid Leukemia Cells and Stem Cells: Correlation with the Expression of Wnt and Hedgehog Targets and Biological and Clinical Features.. Blood, 2012, 120, 2501-2501.	0.6	5
112	Bortezomib-Dexamethasone As Induction Therapy for Light Chain Deposition Disease (LCDD): A Single Center Experience. Blood, 2012, 120, 5027-5027.	0.6	0
113	Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis. Current Signal Transduction Therapy, 2011, 6, 88-98.	0.3	4
114	Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. American Journal of Hematology, 2011, 86, E64-E66.	2.0	9
115	High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis. 2011, 18, 127-129.	1.4	6
116	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer, 2010, 10, 526.	1.1	39
117	3-(2,4-Dichlorophenyl)-4-(1-methyl-1 <i>H</i> -indol-3-yl)-1 <i>H</i> -pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 785-794.	1.3	36
118	Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2.. Blood, 2009, 114, 3840-3840.	0.6	0
119	Hyperforin Blocks Neutrophil Activation of Matrix Metalloproteinase-9, Motility and Recruitment, and Restrains Inflammation-Triggered Angiogenesis and Lung Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 492-500.	1.3	47
120	Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia, 2007, 21, 1060-1069.	3.3	40
121	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. British Journal of Haematology, 2007, 138, 594-602.	1.2	44
122	Towards a new age in the treatment of multiple myeloma. Annals of Hematology, 2007, 86, 159-172.	0.8	31
123	Role of Protein Kinase CK2 in the Retinoic Acid-Induced Differentiation of Acute Promyelocytic Leukemia Cells.. Blood, 2007, 110, 879-879.	0.6	1
124	Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood, 2006, 108, 1698-1707.	0.6	123
125	Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden- β -lactam with a Galloyl Moiety. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 539-546.	1.3	21
126	Global monitoring of influenza: potential contribution of national networks from a French perspective. Expert Review of Anti-Infective Therapy, 2006, 4, 387-393.	2.0	5

#	ARTICLE	IF	CITATIONS
127	Disruption of PLZP in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis. <i>Molecular and Cellular Biology</i> , 2004, 24, 10456-10469.	1.1	53
128	Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 387-400.	1.1	6
129	Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2.. <i>Blood</i> , 2004, 104, 643-643.	0.6	2
130	Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. <i>Science</i> , 2003, 299, 259-262.	6.0	387
131	Modeling Acute Promyelocytic Leukemia in the Mouse: New Insights in the Pathogenesis of Human Leukemias. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 231-248.	0.6	12
132	The theory of APL. <i>Oncogene</i> , 2001, 20, 7216-7222.	2.6	103
133	B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. <i>Cancer</i> , 2000, 89, 1259-1268.	2.0	23
134	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 2000, 96, 647-654.	0.6	7
135	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L240-L250.	1.3	35
136	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€™T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286.	0.6	25
137	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. <i>Journal of Clinical Investigation</i> , 1999, 104, 115-121.	3.9	134
138	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€™T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286.	0.6	11